Paget's disease of bone: There's more than the affected skeletal-a clinical review and suggestions for the clinical practice

Current Opinion in Rheumatology

Volumn 22, Issue 4, 2010, Pages 410-423

  Falchetti, Alberto ^a   Masi, Laura ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Clinical diagnosis of Paget's disease of bone; Ideal path for an optimal clinical management of Paget's disease of bone; Paget's disease of bone; Pathophysiology of Paget's disease of bone

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; ENDOTHELIN 1; OSTEOCALCIN; OSTEOPROTEGERIN; PROTEIN P62;

AGE; ANGIOID STREAK; ARTERY CALCIFICATION; BONE BIOPSY; BONE REMODELING; BONE SCINTISCANNING; BONE TURNOVER; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNICITY; FAMILY HISTORY; GIANT CELL TUMOR; HEARING LOSS; HETEROZYGOTE; HIGH OUTPUT HEART FAILURE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERURICEMIA; MORBIDITY; MORTALITY; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOSARCOMA; PAGET BONE DISEASE; PATHOPHYSIOLOGY; PEYRONIE DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; VIRUS PATHOGENESIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; HUMANS; MUTATION; OSTEITIS DEFORMANS; OSTEOBLASTS;

EID: 77953475972     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32833af61e     Document Type: Review

References (115)

1. Paget J. On a form of chronic inflammation of bones (osteitis deformans). Trans Med-Chir Soc 1877; 60:37-63.
2. Cundy HR, Gamble G, Wattie D, et al. Paget's disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int 2004; 75:358-364.
3. Haddaway MJ, Davie MW, McCall IW, Howdle S. Effect of age and gender on the number and distribution of sites in Paget's disease of bone. Br J Radiol 2007; 80:532-536.
4. Gennari L, Merlotti D, Martini G, Nuti R. Paget's Disease of Bone in Italy. J Bone Miner Res 2007; 21:14-21.
5. Gold DT, Boisture J, Shipp KM, PieperCF, et al. Paget's disease of bone and quality of life. J Bone Miner Res 1996; 11:1897-1904.
6. Kanis JA. Pathophysiology and treatment of Paget's disease of bone. London: Martin Dunitz Ltd; 1991.
7. SeitzS, Priemel M, Zustin J, et al. Paget's disease of bone: histologic analysis of 627 patients. J Bone Miner Res 2009; 24:62-69.
8. Renier JC, Audran M. Progression in length and width of pagetic lesions, and estimation of age at disease onset. Rev Rheum Ed Fr 1997; 64:35-43.
9. Gardner MJ, Guyer PB, Barker DJP. Paget's disease of bone among British migrants to Australia. Br Med J 1978; 2:1436-1437.
10. Gomez Acotto C, Mautalen CA. European origin of patients with Paget's disease of bone in the Buenos Aires area. Eur J Epidemiol 2001; 17:409-411.
11. Griz L, Caldas G, Bandeira C, et al. Paget's disease of bone. Arq Bras Endocrinol Metabol 2006; 50:814-822.
12. Van Staa TP, Selby P, Leufkens HG, et al. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002; 17:465-471.
13. Poor G, Donath J, Fornet B, Cooper C. Epidemiology of Paget's disease in Europe: the prevalence is decreasing. J Bone Miner Res 2006; 21:1545-1549.
14. Barker DJ, Gardner MJ. Distribution of Paget's disease in England, Wales and Scotland and a possible relationship with vitamin D deficiency in childhood. Br J Prev Soc Med 1974; 28:226-232.
15. Detheridge FM, Guyer PB, Barker DJP. European distribution of Paget's disease of bone. Br Med J 1982; 285:1005-1008.
16. Cooper C, Harvey NC, Dennison EM, van Staa TP. Update on the epidemiology of Paget's disease of bone. J Bone Miner Res 2006; 21 (Suppl 2): 3-8.
17. Bone HG. Nonmalignant complications of Paget's disease. J Bone Miner Res 2006; 21 (Suppl 2):64-68.
18. Wermers RA, Tiegs RD, Atkinson EJ, et al. Morbidity and mortality associated with Paget's disease of bone: a population-based study. J Bone Miner Res 2008; 23:819-825.
19. Gardner MJ, Barker DJ. Mortality from malignant tumours of bone and Paget's disease in the United States and in England and Wales. Int J Epidemiol Int J Epidemiol 1978; 7:121-130.
20. Cundy T, McAnulty K, Wattie D, et al. Evidence for secular change in Paget's disease. Bone 1997; 20:69-71.
21. Cooper C, Schafheutle K, Dennison E, Kellingray S, et al. The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res 1999; 14:192-197.
22. Seton M, Choi HK, Hansen MF, et al. Analysis of environmental factors in familial versus sporadic Paget's disease of bone: the New England Registry for Paget's Disease of Bone. J Bone Miner Res 2003; 18:1519-1524.
23. Rendina D, Gennari L, De Filippo G, et al. Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy. J Bone Miner Res 2006; 21:1828-1835.
24. Gennari L, Di Stefano M, Merlotti D, et al. Prevalence of Paget's disease of bone in Italy. J Bone Miner Res 2005; 20:1845-1850.
25. Rebel A, Basle M, Pouplard A, et al. Bone tissue in Paget's disease of bone: ultrastructure and immunocytology. Arthritis Rheum 1980; 23:1104-1114. (Pubitemid 10021685)
26. Mills BG, Frausto A, Singer FR, et al. Multinucleated cells formed in-vitrofrom Pagets bone-marrow express viral antigens. Bone 1994; 15:443-448.
27. Reddy SV, Singer FR, Roodman GD. Bone marrow mononuclear cells from patients with Paget's disease contain measles virus nucleocapsid messenger ribonucleic acid that has mutations in a specific region of the sequence. J Clin Endocrinol Metab 1995; 80:2108-2111.
28. Mee AP, Dixon JA, Hoyland JA, et al. Detection of canine distemper virus in 100% of Paget's disease samples by in situ reverse transcriptase-polymerase chain reaction. Bone 1998; 23:171-175.
29. Helfrich MH, Hobson RP, Grabowski PS, et al. A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res 2000; 15: 2315-2329.
30. Ooi CG, Walsh CA, Gallagher JA, Fraser WD. Absence of measles virus and canine distemper virus transcripts in long-term bone marrow cultures from patients with Paget's disease of bone. Bone 2000; 27:417-421.
31. Kurihara N, Reddy SV, Menaa C, et al. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest 2000; 105:607-614.
32. Reddy SV, Kurihara N, Menaa C, et al. Osteoclasts formed by measles virus infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts. Endocrinology 2001; 142:2898-2905.
33. Friedrichs WE, Reddy SV, Bruder JM, et al. Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res 2002; 17:145-151.
34. Kurihara N, Zhou H, Reddy SV, et al. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. J Bone Miner Res 2006; 21:446-455.
35. Selby PL, Davies M, Mee AP. Canine distemper virus induces human osteoclastogenesis through NF-kappa B and sequestosome 1/p62 activation. J Bone Miner Res 2006; 21:1750-1756.
36. Ralston SH, Afzal MA, Helfrich MH, et al. Multicenter blinded analysis of RT-PCR detection methods for paramyxoviruses in relation to Paget's disease of bone. J Bone Miner Res 2007; 22:569-577.
37. Matthews BG, Afzal MA, Minor PD, et al. Failure to detect measles virus ribonucleic acid in bone cells from patients with Paget's disease. J Clin Endocrinol Metab 2008; 93:1398-1401.
38. Gennari L, Gianfrancesco F, Di Stefano M, et al. SQSTM1 gene analysis and gene-environment interaction in paget's disease of bone. J Bone Miner Res 2010. [Epub ahead of print]
39. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002; 70:1582-1588.
40. Hocking LJ, Lucas GJ, Daroszewska A, et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 2002; 11:2735-2739.
41. Lucas GJ, Hocking LJ, Daroszewska A, et al. Ubiquitin-associated domain mutations of SQSTM1 in Paget's disease of bone: evidence for a founder effect in patients of British descent. J Bone Miner Res 2005; 20:227-231.
42. Lucas GJ, Hocking LJ, Daroszewska A, et al. Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 2004; 19:1122-1127.
43. Morissette J, Laurin N, Brown JP. Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone. J Bone Miner Res 2006; 21:38-44.
44. Bolland MJ, Tong PC, Naot D, et al. Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations. J Bone Miner Res 2007; 22:411-415.
45. Falchetti A, Di Stefano M, Marini F, et al. Genetic Epidemiology of Paget's Disease of Bone in Italy: sequestosome1/p62 Gene Mutational Test and Haplotype Analysis at 5q35 in a Large Representative Series of Sporadic and Familial Italian Cases of Paget's Disease of Bone. Calcif Tissue Int 2009; 84:20-37.
46. Duran A, Serrano M, Leitges M, et al. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 2004; 6:303-309.
47. Rea SL, Walsh JP, Ward L, et al. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype. J Bone Miner Res 2006; 21: 1136-1145.
48. Layfield R, Searle MS. Disruption of ubiquitin-mediated processes in diseases of the brain and bone. Biochem Soc Trans 2008; 36:469-471.
49. Langston AL, Campbell MK, Fraser WD, et al. Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int 2007; 80:1-9.
50. Matthews BG, Naot D, BavaU, et al. Absence of somatic SQSTM1 mutations in Paget's disease of bone. J Clin Endocrinol Metab 2009; 94:691-694.
51. Merchant A, Smielewska M, Patel N, et al. Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget disease of bone. J Bone Miner Res 2009; 24:484-494.
52. Siris ES, Ottman R, Flaster E, Kelsey JL. Familial aggregation of Paget's disease of bone. J Bone Miner Res 1991; 6:495-500.
53. Johnson-Pais TL, Wisdom JH, Weldon KS, et al. Three novel mutations in SQSTM1 identified in familial Paget's disease of bone. J Bone Miner Res 2003; 18:1748-1753.
54. Falchetti A, Di Stefano M, Marini F, et al. Two novel mutations at exon 8 of the Sequestosome 1 (SQSTM1) gene in an Italian series of patients affected by Paget's disease of bone (PDB). J Bone Miner Res 2004; 19:1013-1017.
55. Eekhoff EW, Karperien M, Houtsma D, et al. Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum 2004; 50: 1650-1654.
56. Hocking LJ, Lucas GJ, Daroszewska A, et al. Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences. J Bone Miner Res 2004; 19:1122-1127.
57. Beyens G, Wuyts W, Cleiren E, et al. Identification and molecular characterization of a novel splice-site mutation (G1205C) in the SQSTM1 gene causing Paget's disease of bone in an extended American family. Calcif Tissue Int 2006; 79:281-288.
58. Collet C, Michou L, Audran M, et al. Paget's disease of bone in the French population: novel SQSTM1 mutations, functional analysis, and genotype-phenotype correlations. J Bone Miner Res 2007; 22:310-317.
59. Najat D, Garner T, Hagen T, et al. Characterisation of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Paget's disease of bone. J Bone Miner Res 2009; 24:632-642.
60. Rea SL, Walsh J, Ward L, et al. Sequestosome 1 mutations in Paget's disease of bone in Australia: prevalence, genotype/phenotype correlation and a novel non-UBA domain mutation (P364S) associated with increased NFkB signaling without loss of ubiquitin-binding. J Bone Miner Res 2009; 24:1216-1223.
61. Chung PY, Beyens G, Guanabens N, et al. Founder effect in different European countries for the recurrent P392L SQSTM1 mutation in Paget's disease of bone. Calcif Tissue Int 2008; 83:34-42.
62. Layfield R. The molecular pathogenesis of Paget disease of bone. Expert Rev Mol Med 2007; 9:1-13.
63. Franck WA, Bress NM, Singer FR, Krane SM. Rheumatic manifestations of Paget's disease of bone. Am J Med 1974; 56:592-603.
64. Alvarez L, Guanabens N, Peris P, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 1995; 10:458-465.
65. DelmasPD, Meunier PJ. Drug therapy: the management of Paget's disease of bone. N Engl J Med 1997; 336:558-566.
66. Reid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004; 35:224-230.
67. Meunier PJ, Salson C, Mathieu L, et al. Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop Rel Res 1987; 217:37-44.
68. Shankar S, Hosking DJ. Biochemical assessment of Paget's disease of bone. J Bone Miner Res 2006; 21 (Suppl 2):22-27.
69. Tarquini R, Perfetto F, Tarquini B. Endothelin-1 and Paget's bone disease: is there a link? Calcif Tissue Int 1998; 63:118-120.
70. PirzerR, Tilly N, Sommer U, et al. Endothelin-1 levels in patients with Paget's disease of bone. Exp Clin Endocrinol Diabetes 2005; 113:598-601.
71. Khairi MR, Robb JA, Wellman HN, Johnston CCJr. Radiographs and scans in diagnosing symptomatic lesions of Paget's disease of bone (osteitis deformans). Geriatrics 1974; 29:49-54.
72. Steinbach HL Some roentgen features of Paget's disease. Am J Radiol 1961; 86:950-964.
73. Wilner D, Sherman RS. Roentgen diagnosis of Paget's disease (osteitis deformans). Med Radiogr Photogr 1966; 42:35-78.
74. Wellman HN, Schauwecker D, Robb JA, et al. Skeletal scintimaging and radiography in the diagnosis and management of Paget's disease. Clin Orthop Rel Res 1977; 127:55-62.
75. Mackenzie I, Young C, Fraser WD. Tinnitus and Paget's disease of bone. J Laryngol Otol 2006; 120:899-902.
76. Smith BJ, Eveson JW. Paget's disease of bone with particular reference to dentistry. J Oral Pathol 1981; 10:233-247.
77. Hadjipavlou AG, Gaitanis LN, Katonis PG, Lander P. Paget's disease of the spine and its management. Eur Spine J 2001; 10:370-384.
78. Dove J. Complete fractures of the femur in Paget's disease of bone. J Bone Joint Surg Br 1980; 62-B:12-17.
79. Allen ML, John RL. Osteitis deformans (Paget's disease). Fissure fractures: their etiology and clinical significance. Am J Roentgenol Rad Ther 1937; 38:109-115.
80. Marr DS, Rosenthal DI, Cohen GL, Tomford WW. Rapid postoperative osteolysis in Paget disease: a case report. J Bone Joint Surg Am 1994; 76:274-277.
81. Rubin DJ, Levin RM. Neurologic complications of Paget disease of bone. Endocr Pract 2009; 15:158-166.
82. Briesacher BA, Orwig D, Seton M, et al. Medical care costs of Paget's disease of bone in a privately insured population. Bone 2006; 38:731-737.
83. Monsell EM. The mechanism of hearing loss in Paget's disease of bone. Laryngoscope 2004; 114:598-606.
84. Teufert KB, Linthicum F Jr. Paget disease and sensorineural hearing loss associated with spiral ligament degeneration. Otol Neurotol 2005; 26:387-391.
85. Smith R. Paget's disease and angioid streaks: one complication less? Br J Ophthalmol 1990; 74:577-578.
86. Haworth S. Cardiac output in osteitis deformans. Clin Sci 1953; 12:271-275.
87. Laroche M, Delmotte A. Increased arterial calcification in Paget's disease of bone. Calcif Tissue Int 2005; 77:129-133.
88. Strickberger SA, Schulman SP, Hutchins GM. Association of Paget's disease of bone with calcific aortic valve disease. Am J Med 1987; 82:953-956.
89. Sokullu O, Tabakan A, Sanioglu S, et al. Effect of coexisting Paget's disease on coronary artery bypass operations. J Card Surg 2006; 21:597-599.
90. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62:6538-6544.
91. Reddy SV, Menaa C, Singer FR, et al. Measles virus nucleocapsid transcript expression is not restricted to the osteoclast lineage in patients with Paget's disease of bone. Exp Hematol 1999; 27:1528-1532.
92. Mills BG, Frausto A. Cytokines expressed in multinucleated cells: Paget's disease and giant cell tumors versus normal bone. Calcif Tissue Int 1997; 61:16-21.
93. Cavey JR, Ralston SH, Hocking LJ, et al. Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 2005; 20:619-626.
94. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004; 74:103-106.
95. Franchi A. Pathology of Paget's disease of bone. Clin Cases Miner Bone Metab 2004; 1:203-207.
96. Haibach H, Farrell C, Dittrich FJ, Wick MR. Neoplasms arising in Paget's disease of bone: a study of 82 cases. Am J Clin Pathol 1985; 83:594-600.
97. Mankin HJ, Hornicek FJ. Paget's sarcoma: a historical and outcome review. Clin Orthop Relat Res 2005; 438:97-102.
98. Mangham DC, Davie MW, Grimer RJ. Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation. Bone 2009; 44:431-436.
99. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. J Bone Miner Res 2006; 21 (Suppl 2):58-63.
100. Reifenstein EC Jr, Albright F. Paget's disease: its pathologic physiology and the importance of the complications arising from fracture and immobilization. N Engl J Med 1944; 231:343-355.
101. Jacobs TP, Michelsen J, Polay JS, et al. Giant cell tumor in Paget's disease of bone: familial and geographic clustering. Cancer 1979; 44:742-747.
102. Singer FR, Mills BG. Giant cell tumor arising in Paget's disease of bone: recurrences after 36 years. Clin Orthop Relat Res 1993; 293:293-301.
103. Shaylor PJ, Peake D, Grimer RJ, et al. Paget's osteosarcoma: no cure in sight. Sarcoma 1999; 3:191-192.
104. Gutteridge DH, Gruber HE, Kermode DG, Worth GK. Thirty cases of concurrent Paget's disease and primary hyperparathyroidism: sex distribution, histomorphometry, and prediction of the skeletal response to parathyroidectomy. Calcif Tissue Int 1999; 65:427-435.
105. Brandi ML, Falchetti A. What is the relationship between Paget's disease of bone and hyperparathyroidism? J Bone Miner Res 2006; 21 (Suppl 2):69-74.
106. Genuth SM, Klein L. Hypoparathyroidism and Paget's disease: the effect of parathyroid hormone administration. J Clin Endocrinol Metab 1972; 35:693-699.
107. Siris ES, Clemens TP, McMahon D, et al. Parathyroid function in Paget's disease of bone. J Bone Miner Res 1989; 4:75-79.
108. Ralph DJ, Mirakian R, Pryor JP, Bottazzo GF. The immunological features of Peyronie's disease. J Urol 1996; 155:159-162.
109. Nagant de Deuxchaisnes CN, Krane SM. Paget's disease of bone: clinical and metabolic observations. Medicine (Baltimore) 1964; 43:233-266.
110. Devine CJ Jr, Horton CE. Peyronie's disease. Clin Plastic Surg 1989; 15:405-409.
111. Lyles KW, Gold DT, Newton RA, et al. Peyronie's disease is associated with Paget's disease of bone. J Bone Miner Res 1997; 12:929-934.
112. Hosking D, Meunier PJ, Ringe JD, et al. Paget's disease: diagnosis and management. Br Med J 1996; 312:491-494.
113. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronatefor Paget disease. N Engl J Med 2005; 353:898-908.
114. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007; 22:142-148.
115. Tziomalos K, Florentin M, Krikis N, et al. Persistent effect of zoledronic acid in Paget's disease. Clin Exp Rheumatol 2007; 25:464-466.